Jazz Pharmaceuticals plc Assets, Fair Value Adjustment
Jazz Pharmaceuticals plc (JAZZ) reported Assets, Fair Value Adjustment of $2.50 million for the 3-month period ending 2014-06-30, per its 10-K filed 2016-02-23.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:AssetsFairValueAdjustment · last filed 2016-02-23
- Jazz Pharmaceuticals plc assets, fair value adjustment for the quarter ending 2014-06-30 was $2.50M, a 127.27% increase year-over-year.
- Jazz Pharmaceuticals plc assets, fair value adjustment for the quarter ending 2014-03-31 was $8.00M, a 433.33% increase year-over-year.
- Jazz Pharmaceuticals plc assets, fair value adjustment for the quarter ending 2013-12-31 was $700.00K, a 66.67% decline year-over-year.
- Jazz Pharmaceuticals plc assets, fair value adjustment for the quarter ending 2013-09-30 was $500.00K, a 95.15% decline year-over-year.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2014-06-30 | $2.50M 10-K · filed 2016-02-23 | $10.50M derived: sum of 2 quarters · filed 2016-02-23 | $11.20M derived: sum of 3 quarters · filed 2016-02-23 | $11.70M derived: sum of 4 quarters · filed 2016-02-23 |
| 2014-03-31 | $8.00M 10-K · filed 2016-02-23 | $8.70M derived: sum of 2 quarters · filed 2016-02-23 | $9.20M derived: sum of 3 quarters · filed 2016-02-23 | $10.30M derived: sum of 4 quarters · filed 2016-02-23 |
| 2013-12-31 | $700.00K 10-K · filed 2015-02-24 | $1.20M derived: sum of 2 quarters · filed 2015-02-24 | $2.30M derived: sum of 3 quarters · filed 2015-02-24 | $3.80M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-09-30 | $500.00K 10-K · filed 2015-02-24 | $1.60M derived: sum of 2 quarters · filed 2015-02-24 | $3.10M derived: sum of 3 quarters · filed 2015-02-24 | $5.20M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $1.10M 10-K · filed 2015-02-24 | $2.60M derived: sum of 2 quarters · filed 2015-02-24 | $4.70M derived: sum of 3 quarters · filed 2015-02-24 | $15.00M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $1.50M 10-K · filed 2015-02-24 | $3.60M derived: sum of 2 quarters · filed 2015-02-24 | $13.90M derived: sum of 3 quarters · filed 2015-02-24 | $16.90M derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | $2.10M 10-K · filed 2014-02-25 | $12.40M derived: sum of 2 quarters · filed 2014-02-25 | $15.40M derived: sum of 3 quarters · filed 2014-02-25 | $16.70M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-09-30 | $10.30M 10-K · filed 2014-02-25 | $13.30M derived: sum of 2 quarters · filed 2014-02-25 | $14.60M derived: sum of 3 quarters · filed 2014-02-25 | |
| 2012-06-30 | $3.00M 10-K · filed 2014-02-25 | $4.30M derived: sum of 2 quarters · filed 2014-02-25 | ||
| 2012-03-31 | $1.30M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |